サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1564984

腫瘍分子診断学の世界市場

Oncology Molecular Diagnostics

出版日
ページ情報
英文 158 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
腫瘍分子診断学の世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 158 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

腫瘍分子診断学の世界市場は2030年までに米国で108億米ドルに達する見込み

2023年に52億米ドルと推定される腫瘍分子診断学の世界市場は、分析期間2023-2030年にCAGR 11.1％で成長し、2030年には108億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである乳がんは、CAGR 9.0%を記録し、分析期間終了時には29億米ドルに達すると予測されます。大腸がん分野の成長率は、分析期間中CAGR 14.6%と推定されます。

米国市場は14億米ドルと推定、中国はCAGR14.2%で成長予測

米国の腫瘍分子診断学市場は2023年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに25億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは14.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.7%と9.0%と予測されています。欧州では、ドイツがCAGR約8.5%で成長すると予測されています。

世界の腫瘍分子診断学市場動向と促進要因まとめ

腫瘍分子診断学とは何か、なぜがん医療を変革するのか？

腫瘍分子診断学とは、がん細胞における遺伝子変異、バイオマーカー、その他の分子特性を分析するための分子生物学的手法のことです。このアプローチにより、分子レベルで特定の変異や異常を特定することで、がんの早期かつ正確な発見、予後予測、個別化された治療計画が可能になります。分子診断学は、治療法を個人の遺伝子プロファイルに合わせて調整し、より効果的で的を絞ったがん治療を提供するプレシジョン・オンコロジーに不可欠です。ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、リキッドバイオプシーなどの技術は腫瘍分子診断学で一般的に採用されており、腫瘍医は固形がん、血液がん、転移性疾患の遺伝子変異を検出することができます。がん治療がより個別化された分子生物学的アプローチに移行するにつれて、分子診断学の役割は患者の転帰と生存率を改善するために不可欠なものとなっています。

技術革新は、がん領域における分子診断薬の採用をどのように加速しているか？

技術の進歩は、腫瘍分子診断学の範囲と能力を拡大する上で重要な役割を果たしています。次世代シーケンシング（NGS）はこの分野に革命をもたらし、1回の検査で複数の遺伝子や遺伝子変異の同時解析を可能にしました。この革新的技術により、包括的なゲノム・プロファイリングが可能となり、標的治療の意思決定の指針となる実用的な変異の同定に不可欠です。リキッドバイオプシーもまた、血液中の循環腫瘍DNA（ctDNA）からがん変異を検出する非侵襲的な方法を提供し、普及しつつある最先端技術です。このアプローチは、治療効果をモニタリングし、再発をリアルタイムで検出する上で特に有用です。バイオインフォマティクスとAIを駆使したデータ解析の進歩も分子診断の精度とスピードを高め、複雑なゲノムデータの解釈を容易にしています。このような技術革新により、分子診断はより迅速で、より利用しやすくなり、日常的な腫瘍学的治療においてますます不可欠なものとなっています。

なぜ分子診断学がプレシジョン・オンコロジーと患者の転帰に不可欠なのか？

分子診断学は、個人の腫瘍の遺伝子構成に基づいてがん治療を個別化する、精密腫瘍学の成長分野の中心的存在です。特定の変異やバイオマーカーを同定することで、分子診断学は腫瘍医が、がんを引き起こす遺伝子変化を直接阻害する標的治療を選択することを可能にし、それによって治療効果を向上させ、副作用を最小限に抑えます。例えば、EGFR、ALK、BRCAなどの遺伝子に変異のある患者は、その分子プロファイルに基づいて、より効きやすい特定の標的療法や免疫療法で治療することができます。さらに、分子診断学はがんの早期発見を可能にし、介入や治療が成功する可能性を高める。診断にとどまらず、これらの検査は微小残存病変（MRD）のモニタリング、治療に対する反応の追跡、がん再発の早期徴候の検出などにも使用され、最終的には患者の生存率と生活の質を向上させる。

腫瘍分子診断学市場の成長を促進する要因は何か？

腫瘍分子診断学市場の成長を牽引している要因はいくつかあるが、特にがんの罹患率の上昇と精密医療に対する需要の高まりが挙げられます。世界のがん罹患率の上昇に伴い、ヘルスケアプロバイダーは治療決定の指針として分子診断学への依存度を高めており、高度な検査ソリューションに対する需要の急増につながっています。次世代シーケンシング（NGS）、リキッドバイオプシー、AIによるデータ解析などの技術の進歩により、これらの診断がより正確で利用しやすくなっています。標的治療や免疫療法などの個別化がん治療へのシフトも主要な促進要因であり、分子診断薬はこれらの治療が有効な患者を特定するために不可欠です。さらに、コンパニオン診断薬（患者と適切な治療法のマッチングを支援する検査薬）に対する規制当局の承認が増加していることも、市場拡大に拍車をかけています。がんの早期発見とモニタリングへの注目の高まりと研究開発への投資の増加は、今後数年間、この市場の堅調な成長を維持すると予想されます。

調査対象企業の例（全12件）

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics（Schweiz）AG
  • Siemens Healthineers
  • Sysmex Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP13704

Global Oncology Molecular Diagnostics Market to Reach US$10.8 Billion by 2030

The global market for Oncology Molecular Diagnostics estimated at US$5.2 Billion in the year 2023, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2023-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Colorectal Cancer segment is estimated at 14.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 14.2% CAGR

The Oncology Molecular Diagnostics market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Oncology Molecular Diagnostics Market – Key Trends & Drivers Summarized

What Is Oncology Molecular Diagnostics and Why Is It Transforming Cancer Care?

Oncology molecular diagnostics refers to the use of molecular biology techniques to analyze genetic mutations, biomarkers, and other molecular characteristics in cancer cells. This approach enables early and accurate cancer detection, prognosis, and personalized treatment plans by identifying specific mutations or abnormalities at the molecular level. Molecular diagnostics are essential for precision oncology, where therapies are tailored to an individual's genetic profile, providing more effective and targeted cancer treatment. Techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid biopsy are commonly employed in oncology molecular diagnostics, allowing oncologists to detect genetic variations in solid tumors, hematological cancers, and metastatic diseases. As cancer treatment moves towards more personalized and molecularly driven approaches, the role of molecular diagnostics has become indispensable in improving patient outcomes and survival rates.

How Are Technological Innovations Accelerating the Adoption of Molecular Diagnostics in Oncology?

Technological advancements have played a crucial role in expanding the scope and capabilities of oncology molecular diagnostics. Next-generation sequencing (NGS) has revolutionized the field, enabling the simultaneous analysis of multiple genes and genetic mutations in a single test. This innovation allows for comprehensive genomic profiling, which is essential for identifying actionable mutations that can guide targeted therapy decisions. Liquid biopsy is another cutting-edge technology that is gaining traction, offering a non-invasive method for detecting cancer mutations from circulating tumor DNA (ctDNA) in the blood. This approach is particularly valuable in monitoring treatment response and detecting relapse in real time. Advances in bioinformatics and AI-powered data analysis are also enhancing the accuracy and speed of molecular diagnostics, making it easier to interpret complex genomic data. These technological innovations are making molecular diagnostics faster, more accessible, and increasingly vital in routine oncology care.

Why Is Molecular Diagnostics Crucial for Precision Oncology and Patient Outcomes?

Molecular diagnostics is central to the growing field of precision oncology, where cancer treatments are personalized based on the genetic makeup of an individual’s tumor. By identifying specific mutations and biomarkers, molecular diagnostics allow oncologists to select targeted therapies that directly interfere with the cancer-driving genetic alterations, thereby improving the effectiveness of treatment and minimizing side effects. For example, patients with mutations in genes like EGFR, ALK, or BRCA can be treated with specific targeted therapies or immunotherapies that are more likely to work based on their molecular profile. Additionally, molecular diagnostics enable early cancer detection, increasing the chances of successful intervention and treatment. Beyond diagnosis, these tests are used for monitoring minimal residual disease (MRD), tracking response to therapies, and detecting early signs of cancer recurrence, ultimately improving patient survival rates and quality of life.

What Factors Are Driving Growth in the Oncology Molecular Diagnostics Market?

The growth in the oncology molecular diagnostics market is driven by several factors, most notably the rising incidence of cancer and the increasing demand for precision medicine. As the global cancer burden grows, healthcare providers are increasingly relying on molecular diagnostics to guide treatment decisions, leading to a surge in demand for advanced testing solutions. Technological advancements, including next-generation sequencing (NGS), liquid biopsy, and AI-driven data analysis, are making these diagnostics more precise and accessible. The shift towards personalized cancer therapies, such as targeted therapies and immunotherapies, is another major growth driver, as molecular diagnostics are essential for identifying patients who will benefit from these treatments. Moreover, increased regulatory approvals for companion diagnostics—tests that help match patients with the right therapies—are fueling market expansion. The growing focus on early detection and monitoring of cancer, alongside increasing investments in research and development, is expected to sustain robust growth in this market over the coming years.

Select Competitors (Total 12 Featured) -

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Oncology Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Worldwide Drives Demand for Advanced Oncology Molecular Diagnostics for Early Detection
    • Increased Focus on Personalized and Precision Medicine Expands Addressable Market for Oncology Molecular Diagnostics
    • Advancements in Liquid Biopsy Technology Propel Growth of Non-Invasive Molecular Diagnostics in Oncology
    • The Integration of Next-Generation Sequencing (NGS) in Oncology Diagnostics Spurs Adoption in Precision Oncology
    • Growing Demand for Companion Diagnostics Strengthens the Business Case for Oncology Molecular Diagnostics Solutions
    • Rising Use of Biomarker-Based Diagnostics Accelerates Demand for Molecular Tests in Targeted Cancer Therapies
    • Increasing Application of Molecular Diagnostics in Immuno-Oncology Expands Market Growth Opportunities
    • Technological Advancements in Point-of-Care Diagnostics Drive the Adoption of Molecular Oncology Solutions in Clinical Settings
    • Shift Toward Liquid Biopsies for Cancer Monitoring Generates Demand for Oncology Molecular Diagnostics
    • Growing Demand for Multi-Gene Panel Testing in Cancer Diagnostics Strengthens Business Case for Advanced Molecular Solutions
    • Rising Awareness of Genetic Predisposition and Hereditary Cancer Testing Spurs Growth in Molecular Oncology Diagnostics
    • Increasing Use of AI and Machine Learning in Molecular Diagnostics Expands the Market for Predictive Oncology Solutions
    • Rise of Consumer Genomics and Direct-to-Consumer Genetic Testing Drives Demand for Oncology Molecular Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oncology Molecular Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • JAPAN
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • CHINA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • EUROPE
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • FRANCE
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • GERMANY
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • INDIA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • AFRICA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030

IV. COMPETITION